A Potent Neutralizing Antibody Provides Protection against SARS-CoV-2 Omicron and Delta Variants via Nasal Delivery

Scientists characterized a human antibody, which they previously isolated from a patient, with a broadly authentic virus-neutralizing activity that inhibited the Delta and Omicron variants with half-maximal inhibitory concentrations of 1.69 ng/ml and 54.31 ng/ml, respectively.